Brian P. Booth

6.7k citations

96 papers · 5.7k · 2 hit papers · h-index 36

Impact in

Immunology top 2%
- Biosimilars and Bioanalytical Methods
Oncology top 2%
- HER2/EGFR in Cancer Research

Papers in

Immunology 30
- Biosimilars and Bioanalytical Methods 29
Statistics and Probability 14
- Statistical Methods in Clinical Trials 14

Co-authors: Richard M. Pazdur (17 shared papers)Robert L. Justice (12 shared papers)Rajeshwari Sridhara (13 shared papers)Jogarao V. S. Gobburu (12 shared papers)RUSSELL S. WEINER (3 shared papers)C.T. Viswanathan (3 shared papers)Surendra Kumar Bansal (2 shared papers)Vinod P. Shah (2 shared papers)
Journals: Bioanalysis (18 papers)Clinical Cancer Research (12 papers)The AAPS Journal (8 papers)The Journal of Clinical Pharmacology (4 papers)Canadian Journal of Physiology and Pharmacology (4 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Brian P. Booth

87 papers receiving 5.2k citations

Brian P. Booth's Hit Papers

align trajectories log scale

Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays 2007 · 700 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2007 Pharmaceutical Research
2007 Clinical Cancer Research

Peers

Countries citing papers authored by Brian P. Booth

Since Specialization

Citations

This map shows the geographic impact of Brian P. Booth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian P. Booth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian P. Booth more than expected).

Fields of papers citing papers by Brian P. Booth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian P. Booth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian P. Booth. The network helps show where Brian P. Booth may publish in the future.

Co-authors

The 25 scholars most cited alongside Brian P. Booth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brian P. Booth Line = papers co-authored together Brian P. Booth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 96 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays Pharmaceutical Research ·C.T. Viswanathan, Surendra Kumar Bansal, Brian P. Booth, Anthony J. DeStefano, Mark J. Rose, Jeffrey M. Sailstad, Vinod P. Shah, Jerome P. Skelly Hit paper breakdown →	2007	700
2	Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma Clinical Cancer Research ·Vicki L. Goodman, Edwin P. Rock, Ramzi N. Dagher, Roshni P. Ramchandani, Sophia Abraham, Jogarao V. S. Gobburu, Brian P. Booth, S. Leigh Verbois Hit paper breakdown →	2007	434
3	Sorafenib for the Treatment of Advanced Renal Cell Carcinoma Clinical Cancer Research ·Robert C. Kane, Ann T. Farrell, Haleh Saber, Shenghui W. Tang, Gene M. Williams, Josephine M. Jee, Chengyi Liang, Brian P. Booth	2006	414
4	Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays The AAPS Journal ·C.T. Viswanathan, Surendra Kumar Bansal, Brian P. Booth, Anthony J. DeStefano, Mark J. Rose, Jeffrey M. Sailstad, Vinod P. Shah, Jerome P. Skelly	2007	409
5	Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma Clinical Cancer Research ·Bhupinder Singh Mann, John R. Johnson, Kun He, Rajeshwari Sridhara, Sophia Abraham, Brian P. Booth, Leigh Verbois, David E. Morse	2007	234
6	Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate Clinical Cancer Research ·Michael Holman Brave, Vicki L. Goodman, Edvardas Kaminskas, Ann T. Farrell, William C. Timmer, Sarah Pope, Ravi S. Harapanhalli, Haleh Saber	2008	209
7	Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma The Oncologist ·Robert C. Kane, Ann T. Farrell, Rajanikanth Madabushi, Brian P. Booth, Somesh Chattopadhyay, Rajeshwari Sridhara, Robert L. Justice, Richard M. Pazdur	2009	196
8	Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen Clinical Cancer Research ·John R. Johnson, Martin H. Cohen, Rajeshwari Sridhara, Yeh‐Fong Chen, Gene M. Williams, John Z. Duan, Jogarao V. S. Gobburu, Brian P. Booth	2005	186
9	Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. PubMed ·Amna Ibrahim, Nancy S. Scher, Grant Williams, Rajeshwari Sridhara, Ning Li, Gang Chen, John Charles Leighton, Brian P. Booth	2003	167
10	Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary Clinical Cancer Research ·Katherine Anne Thornton, Geoffrey Kim, Virginia Ellen Maher, Somesh Chattopadhyay, Shenghui W. Tang, Young Jin Moon, Pengfei Song, Anshu Marathe	2012	131
11	Bioanalysis of Antibody–Drug Conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group Position Paper Bioanalysis ·Boris Gorovits, Stephen C. Alley, Sanela Bilic, Brian P. Booth, Surinder Kaur, Phillip Oldfield, Shobha Purushothama, Chetana M. Rao	2013	129
12	Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response Journal of Pharmacokinetics and Pharmacodynamics ·Hongshan Li, Jingyu Yu, Chao Liu, Jiang Liu, Sriram Subramaniam, Hong Zhao, Gideon Michael Blumenthal, David C. Turner	2017	125
13	2010 White Paper on Recent Issues in Regulated Bioanalysis & Global Harmonization of Bioanalytical Guidance Bioanalysis ·Natasha Savoie, Fabio Garofolo, Peter van Amsterdam, Surendra Kumar Bansal, Christopher Beaver, Patrick Bedford, Brian P. Booth, Christopher A. Evans	2010	113
14	FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation Oncology ·Michael Holman Brave, Ann T. Farrell, Sue Ching Lin, Terrance Ocheltree, Sarah Pope Miksinski, Shwu‐Luan Lee, Haleh Saber, Jeanne Fourie	2010	112
15	Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib Clinical Cancer Research ·Maitreyee Hazarika, Xiaoping Jiang, Qi Liu, Shwu‐Luan Lee, Roshni P. Ramchandani, Christine E. Garnett, Micheal S. Orr, Rajeshwari Sridhara	2008	110
16	Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications The AAPS Journal ·Venkatesh Atul Bhattaram, Brian P. Booth, Roshni P. Ramchandani, B. Nhi Beasley, Yaning Wang, Veneeta Tandon, John Z. Duan, Raman K. Baweja	2005	109
17	Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance The AAPS Journal ·Brian P. Booth, Mark E. Arnold, Binodh S. Desilva, Lakshmi S. Amaravadi, Sherri Dudal, Eric Fluhler, Boris Gorovits, Sam H. Haidar	2014	101
18	Pemetrexed in Malignant Pleural Mesothelioma Clinical Cancer Research ·Maitreyee Hazarika, Robert M. White, Brian P. Booth, Yongcheng Wang, Doo Y. Lee Ham, Cheng Yi Liang, Atiqur Rahman, Jogarao V. S. Gobburu	2005	96
19	2012 White Paper on Recent Issues in Bioanalysis And Alignment of Multiple Guidelines Bioanalysis ·Binodh S. Desilva, Fabio Garofolo, Mario L. Rocci, Suzanne Martinez, Isabelle J. Dumont, France Landry, Catherine Dicaire, Gabriella Szekely‐Klepser	2012	94
20	The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making The Journal of Clinical Pharmacology ·Jun Yang, Hong Zhao, Christine E. Garnett, Atiqur Rahman, Jogarao V. S. Gobburu, William F. Pierce, Genevieve Schechter, Jeffery J. Summers	2012	90

About Brian P. Booth

Brian P. Booth is a scholar working on Immunology, Statistics and Probability, Physiology, Biophysics and Hematology, having authored 96 papers that have together received 5.7k indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (29 papers), Clinical Laboratory Practices and Quality Control (16 papers), Statistical Methods in Clinical Trials (14 papers), Advanced Biosensing Techniques and Applications (12 papers), Nitric Oxide and Endothelin Effects (7 papers), Neuropeptides and Animal Physiology (5 papers), Cell Image Analysis Techniques (4 papers) and Cardiac Ischemia and Reperfusion (4 papers). The work is most often cited by research in Immunology (1.3k citations), Oncology (1.3k citations), Hematology (531 citations), Statistics and Probability (281 citations) and Genetics (317 citations). Brian P. Booth has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Richard M. Pazdur, Robert L. Justice, Rajeshwari Sridhara, Jogarao V. S. Gobburu, RUSSELL S. WEINER, C.T. Viswanathan, Surendra Kumar Bansal, Vinod P. Shah, Mark J. Rose and Jeffrey M. Sailstad. Their work appears in journals such as Bioanalysis, Clinical Cancer Research, The AAPS Journal, The Journal of Clinical Pharmacology and Canadian Journal of Physiology and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Brian P. Booth

Impact in

Papers in i

In The Last Decade

Brian P. Booth

Brian P. Booth's Hit Papers

Peers

Countries citing papers authored by Brian P. Booth

Fields of papers citing papers by Brian P. Booth

All Works

About Brian P. Booth

Explore authors with similar magnitude of impact

Papers in